Claims for Patent: 6,071,514

Summary for Patent: 6,071,514

Title:	Methods for treating thrombotic disorders
Abstract:	The present invention provides a method of treatment for patients with a variety of thrombotic disorders including, but not limited to, stroke, venous thrombosis, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, and thrombosis as a result of peripheral vascular surgery. Said treatment is a combination therapy with human aPC and antiplatelet agents including, but not limited to, aspirin (ASA), clopidogrel, ReoPro.RTM. (abciximab), dipyridamole, ticlopidine and IIb/IIIa receptor antagonists. The synergy will result in the ability to reduce the dosages of the agents used in the combination therapy.
Inventor(s):	Grinnell; Brian William (Indianapolis, IN), Jakubowski; Joseph Anthony (Indianapolis, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	09/090,061
Patent Claims:	1. A method of treating a thrombotic disorder in a patient in need thereof, which comprises, administering to said patient a pharmaceutically effective amount of a combination of activated protein C and an antiplatelet agent. 2. The method according to claim 1, wherein said thrombotic disorder is selected from the group consisting of acute thrombotic stroke, venous thrombosis, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, and thrombosis as a result of peripheral vascular surgery. 3. The method according to claim 2, wherein the amount of activated protein C administered is about 2 .mu.g/kg/hr to about 96 .mu.g/kg/hr. 4. The method of claim 3, wherein the activated protein C is administered by continuous infusion for about 24 to about 144 hours. 5. The method according to claim 3, wherein said antiplatelet agent is selected from the group consisting of aspirin (ASA), clopidogrel, abciximab, dipyridamole, ticlopidine and glycoprotein, IIb/IIIa antagonists. 6. A method according to claim 5, wherein said antiplatelet agent is aspirin (ASA). 7. A method according to claim 5, wherein said antiplatelet agent is ticlopidine. 8. A method according to claim 5, wherein said antiplatelet agent is clopidogrel. 9. A method according to claim 5, wherein said antiplatelet agent is abciximab. 10. A method according to claim 5, wherein said antiplatelet agent is dipyridamole. 11. A method according to claim 5, wherein said antiplatelet agent is a glycoprotein IIb/IIIa receptor antagonist. 12. A method of treating a thrombotic disorder in a patient in need thereof, which comprises administering to said patient a pharmaceutically effective amount of an antiplatelet agent and activated protein C such that an activated protein C plasma level of 10 ng/ml to less than 100 ng/ml is achieved. 13. The method of claim 12, wherein said thrombotic disorder is selected from the group consisting of acute thrombotic stroke, venous thrombosis, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, and thrombosis as a result of peripheral vascular surgery. 14. The method of claim 12 wherein the activated protein C is administered by continuous infusion for about 24 to about 144 hours. 15. The method of claim 14 wherein the activated protein C is administered first as a bolus then as a continuous infusion. 16. A method according to claim 5, wherein said antiplatelet agent is aspirin (ASA) and clopidogrel. 17. A method according to claim 5, wherein said antiplatelet agent is aspirin (ASA) and ticlopidine. 18. A method according to claim 5, wherein said antiplatelet agent is aspirin (ASA) and dipyridamole. 19. A method according to claim 5, wherein said antiplatelet agent is aspirin (ASA) and abciximab. 20. A method according to claim 5, wherein said antiplatelet agent is aspirin (ASA) and a glycoprotein IIb/IIIa receptor antagonists.

Details for Patent 6,071,514

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2017-06-05